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Abstract
Background: The metabolic syndrome is a growing global public health problem and highly prevalent in patiens with bipolar disorder. There are a few studies 
about relationship between metabolic syndrome and bipolar disorder subtypes. Objective: The aim of this study was to investigate the prevalence of metabolic 
syndrome (MS) and its individual components in subjects with bipolar I (BD I) and bipolar II (BD II) disorder compared with non-psychiatric controls, and 
to determine the variables affecting MS. Methods: A total of 210 individuals (mean age 42.5 ± 11.87, 58.1% female) of whom 70 had BD I, 70 BD II, and 70 
controls, were included in this study. MS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), 
the adapted ATP III (ATP III-A) and the International Diabetes Federation (IDF) criteria. Results: Participants with BD I had a significantly higher 
prevalence of MS when compared to individuals BD II and non-psychiatric controls according to the NCEP-ATP III, ATP III-A, and IDF 
criteria (ps < 0.01). In individuals with MS, increased waist circumference was the most common abnormality. Logistic regression analysis 
revealed that the presence of physical illness, age and number of cigarettes smoked significantly predicted the presence of MS. Discussion: 
This study showed that MS was more prevalent among BD I individuals compared to BD II and controls, and highlighted the importance of 
regular screening for MS in individuals with BD.
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Introduction
Bipolar disorder (BD) is a chronic disorder that usually starts in 
adolescence and early adulthood, and is characterized by significant 
changes in the affective state and by impaired social and/or 
neuropsychological development1. According to the epidemiological 
field study in the United States of America (USA), the lifetime 
prevalence rate is 0.8% for bipolar I disorder (BD I), and 0.5% for 
bipolar II disorder (BD II)2. The World Health Organization (WHO) 
estimates that BD is currently the sixth leading cause of disability 
worldwide among adults. Depending on unhealthy lifestyle models 
such as high calorie diet, cholesterol intake, smoking and physical 
inactivity, 38% of individuals with BD suffer from cardiovascular 
disease (CVD). Life expectancy compared to the general population is 
13.6 years shorter for male patients, and 12.1 years shorter for female 
patients3. In addition, the long-term use of some antipsychotics 
(AP) or mood stabilizers for treatment may be associated with an 
increased risk of developing obesity, dyslipidemia, diabetes mellitus, 
and metabolic syndrome (MS)4. 
MS leads to an increase in central obesity, fasting blood glucose 
(FBG), blood pressure (BP), and arteriosclerosis associated with 
deteriorating lipid profiles. Insulin resistance (IR) plays a role in its 
pathogenesis. It is becoming increasingly common all over the world. 
The risk of MS increases with age5,6. The prevalence of MS varies 
between 6% and 70%7. According to the results of the Metabolic 
Syndrome Research (METSAR) conducted across Turkey, the 
prevalence of MS was 35% among adults 20 years of age and over8. 
In studies conducted in different countries, it has been reported 
that the prevalence of MS in patients with BD varies between 22.4% 
and 67%9-11. Although there are not many studies undertaken on MS 
in Turkey, the prevalence of MS ranges from 24.7% to 36.7%12,13. It 
has been shown that unhealthy lifestyle habits (smoking, alcohol 
use, malnutrition, and lack of exercise) are frequently present in 
individuals with BD, and that these variables increase the risk for the 
development of MS. The relationship between BD and MS remained 
unchanged even after adjustments for age, race, smoking, physical 
inactivity, carbohydrate intake, and alcohol use4. Obesity is frequently 
associated with MS, and it is common among individuals with BD. 
In these patients, obesity has been associated with bad eating habits, 
lack of exercise, and the use of some psychotropic drugs leading to 
weight gain14. In obese people, the hypothalamic pituitary adrenal 
(HPA) axis may be disrupted due to increased leptin and other 
hormones released from the adipose tissue, which affects normal 
mood regulation, and consequently leads to significant and/or rapid 
mood fluctuations such as depression, mania, or the mixture of both 
mood states15. In individuals with BD, the presence of MS has also 
been found to be associated with a decrease in treatment response, 
a more adverse course of illness, increased frequency of manic and 
depressive episodes, and increased suicide tendency16. 
Therefore, in the current study, our first aim was to investigate the 
prevalence of MS in individuals with BD I, BD II, and non-psychiatric 
controls, and to compare patients with BD with the control subjects 
in terms of their demographics and clinical variables. The second 
aim of the study was to determine which of the individual MS 
components were associated with BD. We also aimed to identify the 
clinical correlates of MS in BD.
Methods
Participants
This study was carried out between 01.03.2016 and 01.07.2016 in the 
Department of Psychiatry at Tokat Gaziosmanpasa University Faculty 
of Medicine (Tokat, Turkey). A total of 210 subjects (age range: 18-65 
years) consisting of 140 euthymic patients diagnosed with either BD I 
or BD II according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5)17 and 70 non-psychiatric control 
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subjects were enrolled in the study. The control group consisted 
of healthy volunteers who did not have any psychiatric diagnoses, 
and who presented to the outpatient clinic of the physical therapy 
department. Participants who suffered from comorbid alcohol- and 
drug-related disorders (except for smoking) were not included in 
the study (because of the low number of alcohol and substance users 
among the participants with BD during their remission period), and 
participants who had mental retardation (MR) and/or pervasive 
developmental disorders were excluded from the study. 
Instruments of assessment
A demographic and clinical data form, which was prepared to 
assess the demographic and clinical features of the participants, was 
completed by the interviewer. Additionally, the Young Mania Rating 
Scale (YMRS)18,19, the Bipolar Depression Rating Scale (BDRS)20,21, the 
Beck Depression Inventory (BDI)22,23 were used to assess the severity 
of the mood episodes of the participants. To calculate the amount 
of cigarettes smoked, we asked the participants how many packs of 
cigarettes they smoked daily and how many years they were smoking 
and the number of packs/year was recorded, the International 
Physical Activity Questionnaire Short Form (IPAQ-SF)24 was used 
to assess the level of their physical activity. The Turkish versions of 
all these scales were used in the study25. 
Procedure
Face to face interviews were held with all of the participants. The 
questionnaires and scales used in the study were filled out by the 
interviewer, and the participants during these interviews. These 
questionnaires and scales were later rated by the interviewer. The 
groups (BD I, BD II, BD I+BD II, total participants) were divided 
into two groups: a) current cigarette smokers (yes = 1) and b) 
non-smokers (no = 0). Firstly the relationship between cigarettes 
smoking and the duration of illness was assessed. Secondly it was 
assessed whether there is a relationship between the amount of 
cigarettes and the duration of illness. Body weight, height, and waist 
circumference (WC) were measured to investigate the diagnostic 
criteria for MS in the participants and healthy controls. The 
participants also underwent blood tests to identify MS parameters. 
Biochemical findings [FBG, high density lipoprotein (HDL), low 
density lipoprotein (LDL), triglyceride (TG)], and BP measurements, 
which are examined routinely for MS, were recorded for all three 
groups. MS was diagnosed according to the criteria of the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATP III), the adapted ATP III (ATP III-A)26,27, and the International 
Diabetes Federation (IDF)28.
Statistical analyses
Independent samples’ t-test, Pearson’s chi-square and one-way 
analysis of variance (ANOVA) were used to determine whether there 
was a statistically significant difference between the means of the 
variables in the different groups. For group comparisions involving 
ANOVA, post-hoc Tukey analyses were performed to identify where 
the group differences were. Binary logistic regression analyses were 
used to assess the proposed relationship between the demographic 
and clinical variables and the presence of MS. A value of p < 0.05 
was considered statistically significant. All statistical analyses were 
performed using a statistical software package (IBM SPSS Statistics 
19, SPSS inc., an IBM Co., Somers, NY). 
Ethical approval
The study was approved by the Clinical Trials Ethics Committee 
of Tokat Gaziosmanpasa University Faculty of Medicine. The 
participants were also informed about the study. Then, written 
informed consent was obtained from the participants who voluntarily 
agreed to participate.
Results
Group comparisons according to demographic and clinical 
characteristics
A total of 210 participants (18-65 years) including 70 participants 
with BD I, 70 participants with BD II, and 70 non-psychiatric controls 
were enrolled in the study. The mean age was 43.51 (±11.75) years 
for the BD I group, 43.17 (±12.97) years for the BD II group, and 
40.83 (±10.78) years for the control group. There was a significant 
difference among non-psychiatric controls and the other groups 
in terms of age (p < 0.001). The number of female participants in 
the BD II group was higher and there was a significant difference 
compared to the other groups (p = 0.003). Non-psychiatric controls 
were more successful in terms of work status than participants with 
BD (p < 0.001). The demographic characteristics of the participants 
are presented in Table 1.
The groups were compared with each other in terms of their 
clinical characteristics. In the BD I group YMRS score (± standard 
Table 1. Demographic characteristics of the participants 
Variables Groups χ2 /F p
BD I BD II Control
Age (years) 43.51 (11.75) 43.17 (12.97) 40.83 (10.78) 11.773 < 0.001
Sex Female 33 (47.1) 52 (74.3) 37 (52.9) 11.775 0.003
Marital status Single 15 (21.4) 21 (30) 9 (12.9) 22.634 0.004
Married 46 (65.7) 34 (48.6) 56 (80)
Divorced 7 (10) 6 (8.6) 4 (5.7)
Separated 2 (2.9) 3 (4.3) 0 (0)
Widow 0 (0) 6 (8.6) 1 (1.4)
Level of education Illiterate 2 (2.9) 6 (8.6) 1 (1.4) 22.420 0.013
Primary school 33 (47.1) 21 (30) 21 (30)
Secondary school 9 (12.9) 10 (14.3) 3 (4.3)
High school 14 (20) 13 (18.6) 26 (37.1)
University 12 (17.1) 20 (28.6) 18 (25.7)
Income level (TL) 974.54 (1021.73) 879.71 (1060.74) 1495.71  (951.60) 1.124  0.327
Employment status Employed 29 (41.4) 22 (31.4) 53 (75.7) 30.212 < 0.001
Pack/year of cigarette smoking 5.75 (9.85) 3.94 (8.23) 3.53 (8.05) 2.156 0.118
Note. Results are presented as mean (standard deviation), or frequency (percentage). BD I: bipolar disorder I; BD II: bipolar disorder II; TL: Turkish Lira.
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deviation (SD) was 0.26 (±0.97), BDRS score (±SD) was 3.1 (±3.05), 
BDI score (±SD) was 4.9 (±4.7), in the BD II group YMRS score (±SD) 
was 0.04 (± 0.36), BDRS score (±SD) was 3.5 (±3.03), BDI score 
(±SD) was 6.66 (±4.78), in the control group BDI score (±SD) was 4.9 
(±4.7), and there was no significant difference between the groups in 
terms of these scale scores. The mean number of depressive episodes 
[± standard deviation (SD)], and the mean total number of mood 
episodes (±SD) were 4.94 (±2.48), and 8.66 (±3.69), respectively. In 
the BD II group, the mean number of depressive episodes (±SD), and 
the mean total number of mood episodes (±SD) were 5.49 (±2.67), 
and 8.67 (±4.27), respectively. There was a significant difference 
between the BD I group and the BD II group in terms of the mean 
number of depressive episodes, and mean total number of mood 
episodes (both p values 0.024). In the BD I group, the mean number 
of manic episodes (± SD), and the mean hypomanic episodes (± SD) 
were 3.0 (± 1.77), and 0.78 (± 1.48), in the BD II group, the mean 
hypomanic episodes 3.21 (±2.19 SD), respectively. The groups did 
not differ from each other on the mean number of manic/hypomanic 
episodes (p = 0.804). The cigarette smokers were twenty-one (30.%) 
participants for the BD I group, nineteen (27.1%) participants for 
the BD II group, and fourteen (20.%) participants for the control 
group. According to the results of statistical analysis, there was not 
found a significant relationship between smoking and duration of 
illness between groups (BD I (χ2 = 0.258, df = 66, p = 0.79), BD II 
(χ2 = 0.073, df = 68, p = 0.472), BD I+BD II (χ2 = 0.320, df = 136, p 
= 0.50), total participants (χ2 = 0.001, df = 208, p = 0.30 ). The mean 
amount of cigarettes (±SD) were 5.75 (±9.85) packs/year in the BD I 
group, 3.94 (±8.23) packs/year for the BD II group, and 3.53 (±8.05) 
packs/year for the control group, respectively. Additionaly, there was 
not a significant correlation between the amount of cigarettes and 
the duration of illness for BD I (correlation coefficient) r = 0.202, 
p = 0.094) and BD II (r = 0.151, p = 0.212). Mood stabilizers and 
combination therapies were significantly more frequently offered 
in the BD I group. There was a significant difference in the use of 
mood stabilizers and combination therapy (AP + mood stabilizers) 
between the BD I group and the BD II group (p = 0.002, p < 001).
Prevalence of metabolic syndrome and the presence of 
metabolic syndrome components according to the groups
In participants with BD who met the diagnostic criteria for MS, 
the prevalence of the individual diagnostic components was as 
follows: 93.4% for abnormal WC, 82.4% for low HDL, 74.7% for 
hypertriglyceridemia, 50.5% for high systolic BP, 48.4% for high 
FBG, 29.7% for high diastolic BP.
There was a statistically significant difference between the BD 
I group, and the BD II and control groups in terms of body mass 
index (BMI), WC, diastolic BP, triglycerides, and FGB (all p values 
< 0.001). On all these parameters, the BD I group had higher levels 
than the other two groups. On the same parameteres, there were no 
statistically significant differences between the BD II group and the 
non-psychiatric controls. Systolic BP was statistically significantly 
different between the BD I group and the non-psychiatric controls, 
and the BD I group had higher levels. There was a statistically 
significant difference in the HDL-cholesterol levels between the BD 
II group, and the non-psychiatric controls and the BD I group (p < 
0.001), and the BD II group had higher levels than the other groups. 
There was a statistically significant difference between the groups 
in terms of the prevalence of metabolic syndrome according to 
different diagnostic criteria (all p values < 0.01). According to the 
diagnostic criteria of the NCEP-ATP-III, the ATP-III-A, and the 
IDF, the prevalence of MS was higher in the BD I group than the 
BD II group and the non-psychiatric controls. The prevalence of MS 
did not differ from each other in the BD II group and the control 
group. Mean scores of the MS components and the prevalence of MS 
according to the groups are presented in Table 2.
Factors associated with metabolic syndrome
The effect of the independent variables sex (coded as female = 0/
male = 2), age, duration of psychiatric illness, presence of comorbid 
physical illness (coded as yes = 1/no = 2), total number of mood 
episodes, total number of hospitalizations, number of cigarette 
smoking (packs/year), total BDRS scores, and exercise status (MET 
(min/week (1 MET = 3,5 mL/kg/dk) on the presence of MS according 
to the IDF criteria was assessed by a binary logistic regression model. 
Because it was the most recent among other MS diagnostic criteria. 
There was a significant relationship between the presence of MS 
and the presence of comorbid physical illness, age, and the number 
of cigarettes smoked (p = 0.001, p = 0.037, p = 0.044, respectively). 
Discussion
MS has also been known as Syndrome X, insulin resistance syndrome, 
Reaven syndrome, and the metabolic cardiovasculer syndrome29. 
MS was associated with a poor course of illness and prognosis in 
individuals with BD, suggesting that MS still is an important issue 
in clinical psychiatric practice30,31. 
In the present study, participants were assessed for MS according 
to the NCEP-ATP III, ATP III-A, and IDF criteria. According to 
the NCEP-ATP III criteria, the prevalence of MS was 57.1% for the 
Table 2. Mean scores of the metabolic syndrome components according to the groups and prevalence of MS
  BD I BD II HC χ² Post-hoc 
comparison
M SD M SD M SD (Tukey HSD) p
BMI (kg/m²) 31.59 6.62 29.06 5.69 27.58 4.4 43.57 BD I>BD II=HC < 0.001
WC 111.69 14.28 104.23 13.4 103.56 11.57 54.78 BD I>BD II=HC < 0.001
Diastolic BP 79.43 8.49 75.21 8.18 76.71 9.59 18.56 BD I> BD II=HC < 0.001
Systolic BP 124.14 13.13 121.0 11.05 118.49 14.74 21.07 BD I> HC=BD II < 0.001
HDL-c 42.94 14.35 53.14 13.13 47.73 13.1 52.22 BD II>HC=BD I < 0.001
TG 169.54 118.17 140.64 95.73 133.33 74.79 42.22 BD I>BD II=HC < 0.001
FBG 110.53 49.26 96.83 24.07 93.57 17.96 13.48 BD I>BD II=HC < 0.001
BD I BD II HC X² p
ATP-III 40 (57.1) 21 (30) 25 (35.7) 11.855 0.003
ATP-
III-A
40 (57.1) 24 (34.3) 25 (35,7) 9.399 0.009
IDF 41 (58.6) 24 (34.3) 26 (37.1) 10.045 0.007
BD I: bipolar disorder I; BD II: bipolar disorder II; HC: healthy control subjects; M: mean score; SD: standard deviation; F: one-way ANOVA; HSD: highly significant difference; BMI: body mass index; WC: waist circumference 
BP: blood pressure; HDL-c: high-density lipoprptein; TG: triglycerides; FBG: fasting plasma glucose; ATP-III: National Cholesterol Education Program Adult Treatment Panel; IDF: Internal Diabetes Federation. 
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BD I group, 30% for the BD II group, 35.7% for the non-psychiatric 
controls, according to the ATP III-A criteria 57.1% for the BD I group, 
34.3% for the BD II group, 35.7% for the non-psychiatric controls 
and according to the IDF criteria 58.6% for the BD I group, 34.3% for 
the BD II group, 37.1% for the non-psychiatric controls. According 
results of previous MS prevalence in participants with BD studies, MS 
prevalence ranged from 17% to 53%27,32-34. MS prevalence has been 
reported to be 18-26% in European countries10,35,36, and 30-49% in 
the USA4,36-38. The lower prevalence rate in European countries has 
been attributed to differing eating habits, ethnicity, and lifestyle4. The 
studies we use in relation to MS prevalence are presented in Table 4.
Focusing specifically on studies of MS in BD, in a study conducted 
in Taiwan where the participants with BD I (n = 15), BD II (n = 16), 
major depressive disorder (MDD) (n = 141), and anxiety disorders 
(n = 36) were compared in terms of the prevalence of MS, it was 
reported that 46.7% BD I, 25% BD II, 22% MDD, and 18.4% anxiety 
disorder participants suffered from MS34. In another study, which 
was conducted in New Zealand, the prevalence of MS was reported 
to be 50% for participants with BD, and 32% for healthy controls16. 
In a study in which participants with BD II without treatment 
(valproate acid and fluoxetine were used if needed) were monitored 
for 12 weeks in terms of their MS parameters, it was reported that 
only the BMI increased during the observation period. Therefore, 
the authors concluded that BD II was more moderate in terms of 
metabolic dysregulation, and that the prevalence of MS in BD II was 
similar to the general population35. In our study, the prevalence of 
MS was lower in the BD II group and the non-psychiatric controls 
than in the BD I group. 
Not many studies were conducted in Turkey in this area of 
research, and in one of these studies, which consisted of 125 
participants, the prevalence of MS was reported 32%8. In another 
study, evaluating the efficacy of agents used for MS treatment in BD, 
60 participants were reported to have MS, with a prevalence rate of 
36.7%13. We obtained a higher MS prevalence for BD I participants 
Table 3. Summary of logistic regression analysis predicting the diagnosis of metabolic syndrome 
  B S.E. OR 95 % CI Wald p
Sex -.357 0.405 0.70 [0.317, 1.546] 0.77 0.37
Age (years) -.038 .018 0.963 [0.929, 0.998] 4.33 0.037
Disorder duration (years) 0.004 0.026 1.004 [0.954, 1.056] 0.019 0.89
Presence of comorbid medical disorder -1.572 0.474 0.208 [0.082, 0.526] 10.98 0.001
Total number of depressive episodes 0.051 0.099 1.052 [0.867, 1.277] 0.267 0.605
Total number of manic episodes -0.253 0.191 0.776 [0.533, 1.130] 1.746 0.186
Total number of hypomanic episodes -0.036 0.109 0.985 [0.779, 1.196] 0.106 0.745
Total number of hospitalizations -0.002 0.201 0.998 [0.673, 1.479] 0.00 0.991
Exercise status (MET) -0.169 0.494 0.844 [0.321, 2.222] 0.117 0.732
Number of cigarettes smoked (packs/
year)
0.083BB 0.040 0.920 [0.850, 0.996 ] 4.248 0.039
BDRS total score 0.124 0.084 1.132 [0.961, 1.335] 2.195 0.138
BD I -0.358 1.123 0.699 [0.077, 6.321] 0.101 0.750
BD II -0.280  1.081 0.756 [0.091, 6.287] 0.067 0.796
Note: Comorbid medical disorder (1: yes, 2: no), Exercise status [1: 600-3000 MET (min/week (1 MET = 3,5 mL/kg/dk)], 2: > 3000 MET min/week). BD I: bipolar disorder I; BD II: bipolar disorder II; 
BDRS: Bipolar Depression Rating Scale. 
Table 4. Summary of studies documenting the rate of metabolic syndrome in bipolar disorder
Author/year Sample size Location MS MS Definition Rate of MS Rate of general population
Fagiolini et al. (2005) 171 BD, BD I-71%, BD II-
26%, BD NOS-3%
USA NCEP-III 30% 23.7%
Cardenas et al. (2008) 98 BD I/II USA NCEP-III 49%  
Birkenaes et al. (2006) 103 Sch, 83 BD I/II Norway NCEP-III 30%  
Fiedorowicz et al. (2008) 60 BD, BD I-59%, BD II-
34%, BD NOS-7%
USA NCEP-III 50% 27.3%
Sicras et al. (2008) 178 BD Spain NCEP-III 24.7% 14.4%
Yumru et al. (2007) 125 BD I Turkey NCEP-III 32%
Salvi et al. (2008) 99 BD Italy NCEP-III and IDF 30% 
(IDF)
25.3% (NCEP-III), 16-17.8%
Correl et al. (2008) 74 BD USA NCEP-III 43.2% 23.7%
Garcia-Portilla et al. 
(2008)
194 BD Spain NCEP-III 22.4% 17.9%
Elmslie et al. (2009) 60 BD and 60 Controlled New Zealand NCEP-III BD 50%  
BD I-40,BD II-18, BD NOS-2     Control 32%  
Chang et al. (2009) 117 BD   Taiwan IDF 2005 33.9% M-20.4%, F-15.3%
van Winkel, de Hert 
(2008)
60 BD   Belgium NCEP-III, Adapted NCEP III 16.7% (NCEP-III)  
      IDF 18.3% (adapted)  
        30.0% (IDF)  
BD I BD II   Cyclothymia Hypomania  
Prevalence of BD 
(Lifetime)
0.2-4 0.3-4.8 0.5-6.3 2.6-7.8
NCEP-III: National Cholesterol Education Program Adult Treatment Protocol; IDF: International Diabetes Federation, BD: bipolar disorder. 
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in our study. Previous studies have reported that the use of lithium, 
valproic acid and atypical antipsychotics (e.g. olanzapine, clozapine) 
contributed to obesity and MS in the BD group, mainly due to their 
effects on appetite and glucose and lipid metabolism32,39. The higher 
prevalence of MS in BD I group in our study may be related to the 
higher use of AP and mood stabilizers in this group. It also differs 
from other studies since BD II participants and non-psychiatric 
controls were also included. Although this finding may have been 
somewhat affected by the geographic differences, these differences 
might also indicate that additional factors, including genetic 
vulnerability and environmental (lifestyle) effects, may have played 
a role in modifying MS prevalence rates in patients with BD33. At 
this point, it should be emphasized that abdominal obesity is one 
of the main causes for the occurence of all the components of MS, 
because adipose tissue plays an important role in lipid and glucose 
metabolism, and because it is responsible for the production of 
various cytokines influencing the development of the syndrome40. In 
studies evaluating the prevalence of obesity in Turkey, the prevalence 
was reported 25 % in Trabzon41, 28% in Ankara42 and Kocaeli43, and 
29% in Mersin44. The prevalence of obesity in Tokat was higher than 
these cities, and it was reported 33.6 % for women, and 12.9 % for 
men45. Therefore, the difference of MS prevalence reported in these 
studies may be due to the differences in the prevalence of obesity, 
which is the major component of MS in the general population.
According to the IDF criteria, the prevalence of MS was 58.6% 
for the BD I group, 43.3% for the BD II group, and 37.1% for the 
non-psychiatric controls. In a study that investigated the prevalence 
of MS with different diagnostic criteria in participants with BD, it was 
determined that the prevalence of MS was 25.3% according to the 
ATP-III criteria, and 30% according to the IDF criteria4. Similarly, 
a higher prevalence of MS was detected with the IDF diagnostic 
criteria in our study. 
The mean values for WC, BMI, systolic BP, diastolic BP, FBG, 
and TG levels were found to be higher in the BD I group compared 
to the BD II group and the control group. These values were similar 
in the BD II group and the control group, there was no significant 
difference between these two groups. In a recent study that compared 
participants with BD with participants with MDD and non-
psychiatric controls in terms of MS parameters, it was reported that 
the mean values of WC, triglycerides, systolic BP, diastolic BP, and 
FBG levels were higher in participants with BD than in participants 
with MDD and in non-psychiatric controls, and there were also 
differences between the MDD group and the control subjects, 
where the levels were higher in the MDD patients than in the non-
psychiatric controls46. Our study compared euthymic participants 
with BD I and BD II with non-psychiatric controls, which differs 
from other studies. Hence, these results are a novel addition to the 
literature.
In our study, the mean HDL-cholesterol levels were found to be 
the highest for the BD II group, and the lowest for the BD I group. 
These findings were in line with the prevalence of MS in our study. 
In a study that compared participants with BD with participants with 
MDD and non-psychiatric controls in terms of their HDL-cholesterol 
levels, the mean HDL-cholesterol levels were significantly the highest 
in non-psychiatric controls and was the lowest in BD I. In this study, 
an inverse relationship was found between the HDL-cholesterol levels 
and MS prevalence, which was similar to our findings46. Therefore 
it may be hypothesized that in patients with BD, HDL-cholesterol 
levels are a predictor for MS frequency, but surely there is a need for 
further studies to confirm this finding.
When analysing the prevalence of each of the components of 
MS in our population, we found that increased WC was the most 
common abnormality (93.4%), followed by abnormalities in low 
HDL-cholesterol levels (82.4%), increased triglyceride levels (74.7%), 
increased systolic BP measurements (50.5%), increased FBG (48.4%) 
levels, and increased diastolic BP measurements (29.7%). The 
majority of studies undertaken in participants with BD indicate that 
increased WC was the most9,10,38,47-49, and increased FBG was the least 
frequently encountered abnormality4,10,38,47,49-52, and our findings are 
also, to a great extent, in line with these previous reports.
Daily exercise time was found to be lower in the BD I group 
compared to the BD II group and the control group. In a study that 
examined the relationship between eating and lifestyle habits and 
metabolic disorders in participants with BD, unhealthy eating habits 
and lack of exercise were found to be higher in participants with BD 
than in healthy participants. In the same study, it was reported that 
unhealthy eating habits and lack of exercise were associated with 
weight gain and obesity53.
Additionaly, relationship between participants smoking 
behavior and duration of illness was examined; there was not found 
a significant relationship between smoking and duration of illness 
and there was not a significant correlation between the amount of 
cigarettes and the duration of illness in our study. However, Medeiros 
et al., found a significant relationship between smoking and duration 
of illness, severity of manic symptoms in bipolar subjects54. Our study 
results were different, this discrepancy can be related to the fact that 
participants were in clinical remission.
The participants were assessed in terms of variables affecting MS, 
and there was a significant relationship between MS and the presence 
of comorbid physical illness, age and number of cigarettes smoked. 
The diagnostic categories of BD I or BD II were not associated with 
the presence of MS. In a study involving participants with BD I and 
BD II in which factors affecting the development of MS were assessed, 
it was reported that there was a relationship between the development 
of MS and age, BD I diagnosis, use of AP or mood stabilizers55. Our 
results are very similar to those reported by Van Winkel et al., in 
which patients with BD and MS were older than those without36. 
Aging is commonly accompanied by a loss of muscle mass and by 
an increase in body fat, especially in the abdomen, and both of these 
changes can increase IR and finally lead to MS28. Additionally, the 
meta-analysis by Sun, Liu and Ning56, based on data from prospective 
studies concluded that active smoking was associated with the 
development of MS. In another study that examined the relationship 
between smoking and metabolic disorders, it was reported that 
smoking was higher in patients diagnosed with MS57. On the other 
hand, another study reported that there was no relationship between 
MS and smoking4. The results of our study add to the literature that 
there might be a significant relationship between MS and smoking. 
The findings of the current study suggest that active and early 
screening of metabolic parameters, including triglycerides, and 
HDL-C levels, WC measurements, and lifestyle interventions, 
including dietary changes and physical activity are absolutely 
essential to managing MS among patients with BD and the general 
population. The Mediterranean diet (MD) is a dietary pattern first 
presented by Ancel Keys in the 1960s58, and it is characterized by a 
high intake of fruits, vegetables, legumes, fish, whole grains, nuts, 
and olive oil; moderate consumption of dairy products and wine; 
and low intake of red and processed meats and foods that contain 
high amounts of added sugars59. The beneficial role of the MD with 
regard to mortality from all causes, cardiovascular disease (CVD) 
and cancer, as well as obesity and type 2 diabetes60,61 has already been 
reported from the results of many epidemiological studies and clinical 
trials. Similar recommendations should proactively be pursued for 
the physical health status of patients with BD, and a closer follow-up 
regarding the metabolic parameters should be part of their routine 
clinical management program.
When the results of the current study are evaluated, it is necessary 
to consider the limitations of the study. The fact that participants 
were evaluated cross-sectionally, and that they were not followed up 
longitudinally, and that all of the patients were in an euthymic period 
might limit the generalizability of the results. Other limitations of 
the study are (i) there was no definitive causal relationship in the 
outcomes, (ii) the study results could not be compared, or were only 
suboptimally compared, with other studies in the literature due to 
lack of similarly designed studies in similar clinical populations, 
(iii) it was not possible to compare the groups which were offered 
psychopharmacological treatment with those who were not, which 
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might be a contributing factor for the development of MS, and (iv) 
did not evaluate the role of comorbid alcohol and substance use.
In light of the high rates of MS observed in all settings, we 
propose that minimum monitoring for all individuals, even those 
with normal baseline tests, should include WC or BMI at these 
time points. Optimal monitoring should also include assessments 
of FBG, triglycerides, HDL-c and BP. Patients treated with drugs 
with potential for weight gain and metabolic side effects should 
be evaluated more frequently in terms of weight and metabolic 
parameters. For the medical treatment of MS, lifestyle changes such 
as weight loss, regular exercise, smoking cessation, healty eating are 
also important. The MD is one of the healthiest dietary patterns, 
and it may help with the prevention and treatment of cardiovascular 
disase, diabetes, hypertension and MS.
In conclusion, this article aimed to draw attention to MS, which 
not only affects patients with BD, but also increases in frequency 
in healthy individuals all over the world, and to emphasize the 
importance of necassary measures to be taken. BD is relatively 
highly comorbid with MS, and appropriate interventions should be 
prioritized against the development of MS in BD. 
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